|
|
Article: Cephalon Transfers Manufacture of ACTIQ(R) to its Salt Lake City Facility; Formulation Change Approved for U.S. Market by FDA.
- Article from:
- PR Newswire
- Article date:
- April 2, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Cephalon, Inc. , announced today that manufacture of ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II] for the U.S. market has been transferred from a contract manufacturer to Cephalon's recently expanded facility in Salt Lake City, Utah. The move follows the February 19, 2003 approval by the U.S. Food and Drug Administration of a new compressed powder formulation of ACTIQ for the management of breakthrough pain in cancer patients who are tolerant to opioid therapy. This formulation, which the Salt Lake City facility has manufactured for the European market since November 2000, replaces the current sugar melt formulation sold in the United States.
"The recent ...